Cargando…

The serum angiotensin-converting enzyme 2 and angiotensin-(1-7) concentrations after optimal therapy for acute decompensated heart failure with reduced ejection fraction

Objective: Elucidation of the role of angiotensin-converting enzyme (ACE) 2 (ACE2)/angiotensin (Ang)-(1-7)/Mas receptor axis in heart failure is necessary. No previous study has reported serial changes in ACE2 and Ang-(1-7) concentrations after optimal therapy (OT) in acute heart failure (AHF) patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hisatake, Shinji, Kiuchi, Shunsuke, Kabuki, Takayuki, Oka, Takashi, Dobashi, Shintaro, Fujii, Takahiro, Ikeda, Takanori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Portland Press Ltd. 2020
Materias:	Cardiovascular System & Vascular Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295637/ https://www.ncbi.nlm.nih.gov/pubmed/32458985 http://dx.doi.org/10.1042/BSR20192701

Ejemplares similares

Cardio-Ankle Vascular Index and C-Reactive Protein Are Useful Parameters for Identification of Ischemic Heart Disease in Acute Heart Failure Patients
por: Kiuchi, Shunsuke, et al.
Publicado: (2017)

Efficacy of Intravenous Administration of Landiolol in Patients With Acute Heart Failure and Supraventricular Tachyarrhythmia
por: Kiuchi, Shunsuke, et al.
Publicado: (2017)

Addition of a renin-angiotensin-aldosterone system inhibitor to a calcium channel blocker ameliorates arterial stiffness
por: Kiuchi, Shunsuke, et al.
Publicado: (2015)

Pulse Pressure and Upstroke Time Are Useful Parameters for the Diagnosis of Peripheral Artery Disease in Patients With Normal Ankle Brachial Index
por: Kiuchi, Shunsuke, et al.
Publicado: (2016)

Early initiation of tolvaptan is associated with early discharge in patients with heart failure regardless of age
por: Kiuchi, Shunsuke, et al.
Publicado: (2022)

Angiotensin-converting enzyme 2 and COVID-19 in cardiorenal diseases
por: Sharma, Ravindra K., et al.
Publicado: (2021)

Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: potential allies in the COVID-19 pandemic instead of a threat?
por: Simko, Fedor, et al.
Publicado: (2021)

Effect of rs4646994 polymorphism of angiotensin-converting enzyme on the risk of nonischemic cardiomyopathy
por: Shen, Jinsheng, et al.
Publicado: (2021)

Effectiveness of Fondaparinux in the Japanese Population with Acute Venous Thromboembolism -A Study Comparing Patients with and without Cancer-
por: Yamashita, Asami, et al.
Publicado: (2022)

Beneficial effects of brief early life angiotensin-converting enzyme inhibition wane with time in sheep with solitary functioning kidney
por: McArdle, Zoe, et al.
Publicado: (2023)

Physiological cyclic stretch up-regulates angiotensin-converting enzyme 2 expression to reduce proliferation and migration of vascular smooth muscle cells
por: Song, Jiantao, et al.
Publicado: (2020)

Association between prognosis and the use of angiotensin‐converting enzyme inhibitors and/or angiotensin II receptor blockers in frail patients with heart failure with preserved ejection fraction
por: Sunaga, Akihiro, et al.
Publicado: (2022)

Lipotoxicity: a driver of heart failure with preserved ejection fraction?
por: Leggat, Jennifer, et al.
Publicado: (2021)

The controversy of using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in COVID-19 patients
por: Harky, Amer, et al.
Publicado: (2021)

Initiation, Continuation, or Withdrawal of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction
por: Gilstrap, Lauren G., et al.
Publicado: (2017)

PKN2 deficiency leads both to prenatal ‘congenital’ cardiomyopathy and defective angiotensin II stress responses
por: Marshall, Jacqueline J.T., et al.
Publicado: (2022)

Inhibition of smooth muscle cell death by Angiotensin 1-7 protects against abdominal aortic aneurysm
por: Jadli, Anshul S., et al.
Publicado: (2023)

CGP42112: the full AT(2) receptor agonist and its role in the renin–angiotensin–aldosterone system: no longer misunderstood
por: Restrepo, Yazmin M., et al.
Publicado: (2022)

Angiotensin-Converting Enzyme Inhibitor Therapy Effects in Patients With Heart Failure With Preserved and Mid-Range Ejection Fraction
por: Safonova, Julia, et al.
Publicado: (2021)

Angiotensin Converting Enzymes
por: Wong, Marty K.S.
Publicado: (2016)

Angiotensin converting enzyme
por: Wong, Marty Kwok-Shing
Publicado: (2021)

Hospitalization Rates in Patients with Heart Failure and Reduced Ejection Fraction Initiating Sacubitril/Valsartan or Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers: A Retrospective Cohort Study
por: Houchen, Emma, et al.
Publicado: (2022)

Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction
por: ter Maaten, Jozine M., et al.
Publicado: (2020)

Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Gersh, Felice L.
Publicado: (2020)

Angiotensin-Converting Enzyme-2
por: Clarke, Nicola E., et al.
Publicado: (2013)

Angiotensin-converting enzyme activity and inhibition in dogs with cardiac disease and an angiotensin-converting enzyme polymorphism
por: Meurs, Kathryn M, et al.
Publicado: (2017)

Dietary Potassium Downregulates Angiotensin-I Converting Enzyme, Renin, and Angiotensin Converting Enzyme 2
por: Vio, Carlos P., et al.
Publicado: (2020)

Angiotensin-(1-7), Angiotensin-Converting Enzyme 2, and New Components of the Renin Angiotensin System
por: Trask, Aaron J., et al.
Publicado: (2009)

In reply—Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Renin‐angiotensin aldosterone profile before and after angiotensin‐converting enzyme‐inhibitor administration in dogs with angiotensin‐converting enzyme gene polymorphism
por: Adin, Darcy, et al.
Publicado: (2020)

Angiotensin-converting enzyme 2 and new insights into the renin–angiotensin system
por: Lambert, Daniel W., et al.
Publicado: (2008)

Early Initiation of Tolvaptan is Associated with Early Discharge in Elderly Heart Failure Patients
por: Kiuchi, Shunsuke, et al.
Publicado: (2021)

Angiotensin-Converting Enzyme Inhibitors and Angioedema
por: Sánchez-Borges, Mario, et al.
Publicado: (2010)

Angiotensin-converting Enzyme Genetic Polymorphism
por: Wiwanitkit, Somsri, et al.
Publicado: (2014)

Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Angiotensin-Converting Enzyme 2 Levels: A Comprehensive Analysis Based on Animal Studies
por: Kriszta, Gábor, et al.
Publicado: (2021)

The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Moretti, Myla E., et al.
Publicado: (2012)

Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on hemoglobin levels
por: Ajmal, Adnan, et al.
Publicado: (2013)

Angiotensin-converting enzyme 2 expression is not induced by the renin–angiotensin system in the lung
por: Baba, Ryuta, et al.
Publicado: (2020)

Association Between Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Suicide
por: Mamdani, Muhammad, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_k1o2cctb5veuo1b5sdoje78ls6